Claims:

1. The use of a ~~A~~ compound that is~~selected from~~ seladelpar or a salt~~and the salts~~ thereof in the manufacture of a medicament for ~~use in~~ treating a cholangiopathy in a subject who is intolerant of, or who has an inadequate response to, at least one of obeticholic acid and a fibrate.

2. The ~~compound for~~ use of claim 1 where the compound is a seladelpar L-lysine salt.

3. The ~~compound for~~ use of claim 2 where the compound is seladelpar L-lysine dihydrate salt.

4. The ~~compound for~~ use of any one of claims 1 to 3 where the medicament~~compound~~ is to be administered orally.

5. The ~~compound for~~ use of any one of claims 1 to 4 where the amount of the compound is equivalent to 0.5 - 50 mg/day of seladelpar.

6. The ~~compound for~~ use of claim 5 where the amount of the compound is equivalent to 1 - 25 mg/day of seladelpar.

7. The ~~compound for~~ use of claim 6 where the amount of the compound is equivalent to 2 - 10 mg/day of seladelpar.

8. The ~~compound for~~ use of claim 7 where the amount of the compound is equivalent to 5 mg/day or 10 mg/day of seladelpar.

9. The ~~compound for~~ use of any one of claims 1 to 8 where the medicament~~compound~~ is to be administered once/day.

10. The ~~compound for~~ use of any one of claims 1 to 9 where the cholangiopathy is primary biliary cholangitis.

11. The ~~compound for~~ use of any one of claims 1 to 9 where the cholangiopathy is primary sclerosing cholangitis.

12. The ~~compound for~~ use of any one of claims 1 to 9 where the cholangiopathy is progressive familial intrahepatic cholestasis.

13. The ~~compound for~~ use of any one of claims 1 to 9 where the cholangiopathy is Alagille syndrome.

14. The ~~compound for~~ use of any one of claims 1 to 9 where the cholangiopathy is cystic fibrosis associated cholangiopathy.

15. The ~~compound for~~ use of any one of claims 1 to 9 where the cholangiopathy is autoimmune cholangitis.

16. The ~~compound for~~ use of any one of claims 1 to 9 where the cholangiopathy is graft-versus-host disease involving the liver.

17. The ~~compound for~~ use of any one of claims 1 to 16 where the subject is naïve to ursodeoxycholic acid.

18. The ~~compound for~~ use of any one of claims 1 to 16 where the subject is intolerant of, or has an inadequate response to, ursodeoxycholic acid.

19. The ~~compound for~~ use of any one of claims 1 to 18 where the subject is intolerant of, or has an inadequate response to, obeticholic acid.

20. The ~~compound for~~ use of any one of claims 1 to 19 where the subject is intolerant of, or has an inadequate response to a fibrate.